New immunotherapy shows reduction in tumor size for NSCLC patients
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn more »
M7824, an immunotherapy candidate being developed by EMD Serono, reduced tumor size in a significant number of patients with advanced non-small cell lung cancer (NSCLC), Phase 1 data shows. It’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.
Find the full press statement and further information in this article.